Atopic Dermatitis
Latest News
AAAAI/ACAAI Joint Task Force Issues Updated ‘Practice-Changing’ Guidelines to Manage AD
“There’s something in here for all clinicians — from primary care to AD experts — and patients may benefit as well, so the key individual...
Latest News
Expert Highlights Biologics in the Pipeline for Atopic Dermatitis
“It’s truly an exciting time because we have a lot of different treatments that target IL-4 and other receptors,” Dr. David Rosmarin said.
Latest News
US Dermatologic Drug Approvals Rose Between 2012 and 2022
The study authors identified 52 new drug applications and 26 supplemental new indications approved by the FDA for dermatologic indications between...
Conference Coverage
Which Tools Are Best to Streamline In-Office Assessments of Eczema Patients?
Choose an assessment tool that works for you within your practice setting.
From the Journals
Experimental Topical Drug Shows Promise for Atopic Dermatitis and Plaque Psoriasis
PDE4 inhibitors are a promising therapeutic target for inflammatory diseases because “they can increase cyclic adenosine monophosphate levels and...
Conference Coverage
Expert Frames Factors to Consider Among Atopic Dermatitis Treatment Options
“There isn’t going to be a one-size-fits-all approach.”
Latest News
‘Milestone’ Study Zeros in on 5-Year Safety Data From Upadacitinib Trials
“This is the longest safety study ever published for any systemic drug for AD,” Christopher G. Bunick, MD, said.
Conference Coverage
What’s the Real Prevalence of Conjunctivitis in AD Patients Treated With Dupilumab?
“About 2% of people treated with dupilumab are going to get clinically very meaningful conjunctivitis that may be therapy limiting.”
Latest News
‘Real-World’ Registry Study of Upadacitinib Supports Clinical Trial Data
“We know from clinical trials that upadacitinib is effective, but we have very little real-world experience on its effectiveness,”...
Latest News
Paradoxical Eczema Risk Low With Biologic Psoriasis Treatments
The study included data for all currently available biologics, “originating from more than 160 dermatology centers in the UK and Ireland,” the...
Latest News
How does lebrikizumab perform across different racial and ethnic subgroups?
Prior use of systemic therapy was lower in the Black and “other” subgroups, compared with other racial subgroups.